Cellectis
  • About
    Our mission
    Governance
    Partners
  • Science
    Our Genome Engineering Platform
    TALEN® Technology
    In-House Manufacturing
  • Pipeline
    Product Candidates
  • Investors
    IR Overview
    News
    • Press releases
    • Events and Webcasts
    Presentations
    • Corporate presentations
    • Scientific presentations
    • Scientific publications
    Corporate Governance
    • Board of Directors
    • Executive Committee
    • External Auditors
    • Governance Documents
    • General meetings
    Financial Information
    • SEC filings
    • Financial statements
    • Voting Rights & Share Capital
    • Stock information
    Shareholders Services
    • IR Inquiries
    • IR FAQ
  • Careers
    Our culture
    Job opportunities
  • Contact us
LinkedinX FR
› Investors › Scientific publications
  • About
    • Our mission
    • Governance
    • Partners
  • Science
    • Our Genome Engineering Platform
    • TALEN® Technology
    • In-House Manufacturing
  • Pipeline
    • Product Candidates
  • Investors
    • IR Overview
    • News
      • Press releases
      • Events and Webcasts
    • Presentations
      • Corporate presentations
      • Scientific presentations
      • Scientific publications
    • Corporate Governance
      • Board of Directors
      • Executive Committee
      • External Auditors
      • Governance Documents
      • General meetings
    • Financial Information
      • SEC filings
      • Financial statements
      • Voting Rights & Share Capital
      • Stock information
    • Shareholders Services
      • IR Inquiries
      • IR FAQ
  • Careers
    • Our culture
    • Job opportunities
  • Contact us
FR
LinkedinX

Scientific publications

All 2025 2024 2023 2022 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2003 2002
21
Dec 2009
19:45 E.S.T.

Generation of redesigned homing endonucleases comprising DNA-binding domains derived from two different scaffolds

Grizot S, Epinat JC, Thomas S, Duclert A, Rolland S, Pâques F, Duchateau P.
Nucleic Acids Res. 2010 Apr;38(6):2006-18. doi: 10.1093/nar/gkp1171. Epub 2009 Dec 21.
Read more
21
Oct 2009
23:00 E.S.T.

Reduced immunoglobulin class switch recombination in the absence of Artemis

Rivera-Munoz P, Soulas-Sprauel P, Le Guyader G, Abramowski V, Bruneau S, Fischer A, Pâques F, de Villartay JP.
Blood, 22 October 2009, Vol. 114, No. 17, pp. 3601-3609.
Read more
8
Oct 2009
23:00 E.S.T.

Targeted gene modifications in drug discovery and development

Cabaniols JP, Mathis L, Delenda C.
Curr Opin Pharmacol. 2009 October; 9(5):657-63.
Read more
18
Aug 2009
13:59 E.S.T.

Targeted approaches for gene therapy and the emergence of engineered meganucleases

Galetto R, Duchateau P, Pâques F.
Expert Opinion on Biological Therapy, October 2009, Vol. 9, No. 10, Pages 1289-1303
Read more
6
Jul 2009
23:00 E.S.T.

Efficient targeting of a SCID gene by an engineered single-chain homing endonuclease

Grizot S, Smith J, Daboussi F, Prieto J, Redondo P, Merino N, Villate M , Thomas S, Lemaire L, Montoya G, Blanco FJ, Pâques F, Duchateau P.
Nucleic Acids Research, Volume 37, Issue16, 5405-5419
Read more

Media contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US
cellectis

Clinical-stage biotech · Dual-listed on Nasdaq (CLLS) and Euronext Growth (ALCLS).
Paris · New York · Raleigh.

  • ABOUT
    • Our mission
    • Governance
    • Partners
  • SCIENCE
    • In-House Manufacturing
    • PulseAgile Technology
    • TALEN® Technology
    • Understanding Gene Editing
  • PIPELINE
    • Product Candidates
    • BALLI-01 Trial
    • NATHALI-01 Trial
    • Patients
  • INVESTORS
    • Events
    • Corporate presentations
    • Scientific presentations
    • Scientific publications
    • Governance Documents
    • ESG report
    • Shareholders Meetings
    • SEC filings
    • Financial statements
    • Voting Rights & Share Capital
    • Stock information
    • PDMR Notifications
    • IR Inquiries
    • IR FAQ
  • Careers
    • Our culture
    • Job opportunities
© 2026 Cellectis — All rights reserved
  • Legal notice
  • Community Guidelines